Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 4Urinary Bladder Neoplasms 3Neoplasm Metastasis 3Recurrence 2Urethral Neoplasms 1Ureteral Neoplasms 1Stomach Neoplasms 1Ovarian Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Multiple Myeloma 1Melanoma 1Lymphoma 1Lung Neoplasms 1Kidney Neoplasms 1Head and Neck Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma in Situ 1Breast Neoplasms 1

Interventions

durvalumab 2Magnetic Resonance Imaging 2Electrocardiography 2Diphenhydramine 2Cystoscopy 2Biopsy 2Acetaminophen 2valrubicin 1fludarabine phosphate 1fludarabine 1aldesleukin 1Tomography, X-Ray Computed 1Standard of Care 1Respiratory Function Tests 1Prochlorperazine 1Positron-Emission Tomography 1Ondansetron 1O(6)-codeine methyl ether 1Nicotine Replacement Therapy 1Mitomycin 1Meperidine 1Loperamide 1Interleukin-2 1Innovar 1Indomethacin 1Hydroxyzine 1Histamine Antagonists 1Granisetron 1Gemcitabine 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Carcinoma in Situ × ALT-801 × Clear all
NCT01625260 2024-07-19

A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer

Altor BioScience

Phase 1/2 Terminated
12 enrolled 13 charts
Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma in Situ, Carcinoma, Transitional Cell, Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡